|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Time to coronary angiography and outcomes among patients with high-risk non-ST-segment-elevation acute coronary syndromes 显示文摘 | Tricoci P Lokhnygina Y Berdan LG | 2007 | Circulation2007，116，： | 1 |
| 2 | Time to coronary angiography and outcomes among patients with high-risk non ST- segment elevation acute coronary syndromes: results from the SYNERGY trial显示文摘 | Tricoci P Lokhnygina Y Berdan LG | 2007 | Circulation2007，116，23： | 1 |
| 3 | Effect of aliroeumab, a monoclonal antibody to PCSK9, on long-term cardiovascular out- comes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial 显示文摘 | Schwartz GG Bessac L Berdan LG | 2014 | Am Heart J2014，168，5： | 1 |
| 4 | Effect of a1irocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial 显示文摘 | Schwartz GG Bessac L Berdan LG | 2014 | Am Heart J2014，168，5： | 1 |
| 5 | Maintenance of clinical benefit at 6 months in patients treated with platelet glycoprotein Ⅱ b/Ⅲls inhibitor eptifibatide versus placebo during an acute ischemic coronary event (abstr) 显示文摘 | Lincoff AM Berdan LG | 1998 | Circulation1998，，： | 1 |
| 6 | Effectof alirocumab, a monoclonal antibody to PCSK9, on long-termcardiovascular outcomes following acute coronary syndromes:rationale and design of the ODYSSEY outcomes trial 显示文摘 | Schwartz GG Bessac L Berdan LG | 2014 | AmHeart J2014，168，5： | 1 |
| 7 | Effect of alirocumab,a monoclonal antibody to PCSK9,on long-term cardiovascular outcomes following acute coronary syndromes:rationale and design of the ODYSSEY outcomes trial显示文摘 | SCHWARTZ GG BESSAC L BERDAN LG | 2014 | Am Heart J2014，168，5： | 1 |
| 8 | Time to coronaix angiography and outcomes among patients with high-risk non ST- segment elevation acute coronary syndromes: results from the SYNERGY trial 显示文摘 | Trieoci P Lokhnygina Y Berdan LG | 2007 | Circulation2007，116，23： | 1 |
| 9 | Effect of alirocumab, a monoelonal antibody to PCSK9, on long-term cardiovascular out- comes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial显示文摘 | Schwartz G G Bessac L Berdan LG | 2014 | Am Heart J2014，168，5： | 1 |
| 10 | Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial 显示文摘 | Schwartz GG Bessac L Berdan LG | 2014 | Am Heart J2014，168，5： | 1 |
| 11 | Time to coronary angiography and outcomes among patients with high- risk non ST- SEGMENT - elevation a cute coronary syndrome:resule from the SYNERGY trial显示文摘 | Tricoci P Lokhnygina Y Berdan LG | 2007 | Circulation2007，116，： | 1 |
| 12 | Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial显示文摘 | Schwartz GG Bessac L Berdan LG | 2014 | Am Heart J2014，168，5： | 1 |
| 13 | Effect of alirocum- ab,a monoclonal antibody to PCSK9 ,on long-term cardiovas- cular outcomes following acute coronary syndromes:rationale and design of the odyssey outcomes trial 显示文摘 | Schwartz GG Bessac L Berdan LG | 2014 | Am Heart J2014，168，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员